Psychedelic Drugs Market is growing with factors such as increased research activities among scientists in the field of psychedelic medicine, increasing prevalence of depression and mental disorders and increased treatment options for people suffering from depression and mental disorders driving the growth of North America psychedelic drugs market
Psychedelic drugs market has shown an increasing prevalence of depression and mental disorders which are increasing demand of psychedelic drugs. Although, regulations imposed on psychedelic drugs restricts the growth of the market.
Psychedelic Drugs Market Scenario
According to Data Bridge Market Research, Jazz Pharmaceuticals, Inc. is the leader for North America psychedelic drugs market and the company holds estimated market share of approximately 70% to 80% of the total market. Market leader Jazz Pharmaceuticals, Inc. has an estimated market share of approximately 75.00% in American Jazz Pharmaceuticals, Inc. The U.S. is a leader in psychedelic drugs and furthermore, the company is continuously involved in the development of new products to increase its portfolio of psychedelic drugs. Jazz Pharmaceuticals, Inc.'s psychedelic drugs sales revenue has grown drastically by 16% to generate sales revenue of USD 1,644.95 million 2019 compared to 2018.
- In January 2020, Jazz Pharmaceuticals, Inc., presented a new drug application (NDA) for JZP-258, a novel product of Oxybet, which has 1000 to 1500 mg less sodium than Xyrem and is highly used with narcolepsy and cataplexy. Kindness is used to treat sleep. This submission will increase the company's footprint in the U.S. market as it is a novel product and will increase revenue if approved.
Trends Impacting the Market
Now the question is which other regions Jazz Pharmaceuticals, Inc., and Johnson & Johnson Services Inc, are targeting? Data Bridge Market Research has forecasted a large growth in North America psychedelic drugs market and the market leaders such as Johnson & Johnson Services, Inc. and Jazz Pharmaceuticals, Inc. are targeting the U.S. and Canada to be their next revenue pockets for 2020. Data Bridge Market Research new reports highlight the major growth factors and opportunities in North America psychedelic drugs market.
For more analysis on the North America psychedelic drugs market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=north-america-psychedelic-drugs-market
Scope of Psychedelic Drugs Market
All country based analysis of the North America psychedelic drugs market is further analyzed based on maximum granularity into further segmentation. On the basis of source, the market is segmented into synthetic and natural. On the basis of type, the market is segmented into dissociatives, empathogens, and serotonergic (classical psychedelic drugs). On the basis of application, the market is segmented into narcolepsy, treatment-resistant depression, post-traumatic stress disorder (PTSD), major depressive disorder, others. On the basis of route of administration, the market is segmented into oral, intranasal, parenteral, others. On the basis of drugs, the market is segmented into gamma hydroxybutyric acid (GHB), ketamine, 3, 4-methylenedioxymethamphetamine (ecstasy), psilocybin. On the basis of end user, the market is segmented into hospitals, speciality clinic, research organisation, others. On the basis of distribution channel, the market is segmented into hospital pharmacy, compounding pharmacy, others.
To know more about the study https://www.databridgemarketresearch.com/reports/north-america-psychedelic-drugs-market
Key Pointers Covered in the Psychedelic Drugs Market Industry Trends and Forecast to 2027
- Psychedelic Drugs Market Size
- Market Regulatory Framework and Changes
- Psychedelic Drugs Market Pipeline
- Mental Disorders Epidemiology
- Practicing Psychiatrists Data
- Recent Developments for Market Competitors
- Recent market Value for Different Regions
- Sales Data for Market Competitors
- Key Vendors and Disruptors Study
Key Market Competitors Covered in the Report
- Johnson & Johnson Services, Inc.
- Jazz Pharmaceuticals, Inc.
- Celon Pharma SA
- COMPASS
- usonainstitute.org
- Develco pharma schweiz ag
- Doughlas pharmaceuticals limited
- NeuroRX, Inc.
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals, LLC.
- AVADEL PHARMACEUTICALS, PLC
Above are the key players covered in the report, to know about more and exhaustive list of psychedelic drugs companies contact us https://www.databridgemarketresearch.com/toc/?dbmr=north-america-psychedelic-drugs-market
Research Methodology: Psychedelic Drugs Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
- Demand Side: Psychiatrists, Psychedelic Therapists, Researchers, Practitioners, and Activists, Academician, Distributors, Hospitals, Nurses, and Industrial Professionals
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others
Related Report
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/
